IL-1-blocking agents, including canakinumab, anakinra, and rilonacept, have been developed and approved for clinical use in the treatment of autoinflammatory and autoimmune diseases [1, 252–254, 271]. This evidence concerns the gene IL1A and autoimmune disease.